AIM:To estimate hepatitis B virus (HBV) infection testing rate in cancer patients before chemotherapy with a focus on HBV reactivation.METHODS:A retrospective study was conducted from January 1,2009 to June 30,2010.In...AIM:To estimate hepatitis B virus (HBV) infection testing rate in cancer patients before chemotherapy with a focus on HBV reactivation.METHODS:A retrospective study was conducted from January 1,2009 to June 30,2010.Inclusion required that patients be na ve to cancer chemotherapy but have indications for it.Patients who did not receive chemotherapy for any reason were excluded.Important clinical information,such as the levels of HBV DNA and serological markers were collected.HBV reactivation was defined as an increase in serum HBV DNA to > 1 log higher than that of the pre-exacerbation baseline,or serum HBV DNA conversion from negative to positive.HBV DNA levels > 1000 copies/mL were defined as HBV DNA positive.The χ 2 or Fisher's exacttest was used for analysis of categorized data.Multiple logistic regression analysis was used to estimate the odd ratio and 95%CI of the HBV screening rate.RESULTS:Of 6646 patients,5616 (84.5%) received chemotherapy.Only 17.1% of the cancer patients received pre-chemotherapy HBV testing (43.2% for hematological malignancies and 14.9% for solid tumors).Patients who had received rituximab therapy,had elevated aminotransferase levels,or had hematological malignancies were more likely to receive HBV testing.The prevalence of hepatitis B surface antigen (HBsAg) positivity was 13.4%.HBV reactivation (appearance of HBV DNA or an increase in HBV DNA levels by 1 log 10) was observed in 33.1% (53/160) of the patients after chemotherapy.Among patients without prophylactic antiviral therapy,the reactivation rate was 43.9% (43/98) in the solid tumor group.Two reactivation cases occurred in patients who were HBsAg negative,but positive for hepatitis B core antibody.HBV reactivation was more likely to occur in patients with lymphoma,high levels of HBV DNA,or hepatitis B e antigen,and in men.CONCLUSION:Less than 20% of patients received HBV testing before chemotherapy.HBV reactivation would have occurred in about 50% of infected patients with solid tumors without antiviral prophylaxis.展开更多
There are several malignancies of the digestive system(including gastric, pancreatic and colorectal cancers, and hepatocellular carcinoma), which are the most common types of cancer and a major cause of death worldwid...There are several malignancies of the digestive system(including gastric, pancreatic and colorectal cancers, and hepatocellular carcinoma), which are the most common types of cancer and a major cause of death worldwide. MicroRNA(miR)-7 is abundant in the pancreas, playing an important role in pancreatic development and endocrine function. Expression of miR-7 is downregulated in digestive system malignancies compared with normal tissue. Although there are contrasting results for miR-7 expression, almost all research reveals that miR-7 is a tumor suppressor, by targeting various genes in specific pathways. Moreover, miR-7 can target different genes simultaneously in different malignancies of the digestive system. By acting on many cytokines, miR-7 is also involved in many gastrointestinal inflammatory diseases as a significant carcinogenic factor. Consequently, miR-7 might be a biomarker or therapeutic target gene in digestive system malignancies.展开更多
基金Supported by The National Natural Science Foundation of China,No.30801373
文摘AIM:To estimate hepatitis B virus (HBV) infection testing rate in cancer patients before chemotherapy with a focus on HBV reactivation.METHODS:A retrospective study was conducted from January 1,2009 to June 30,2010.Inclusion required that patients be na ve to cancer chemotherapy but have indications for it.Patients who did not receive chemotherapy for any reason were excluded.Important clinical information,such as the levels of HBV DNA and serological markers were collected.HBV reactivation was defined as an increase in serum HBV DNA to > 1 log higher than that of the pre-exacerbation baseline,or serum HBV DNA conversion from negative to positive.HBV DNA levels > 1000 copies/mL were defined as HBV DNA positive.The χ 2 or Fisher's exacttest was used for analysis of categorized data.Multiple logistic regression analysis was used to estimate the odd ratio and 95%CI of the HBV screening rate.RESULTS:Of 6646 patients,5616 (84.5%) received chemotherapy.Only 17.1% of the cancer patients received pre-chemotherapy HBV testing (43.2% for hematological malignancies and 14.9% for solid tumors).Patients who had received rituximab therapy,had elevated aminotransferase levels,or had hematological malignancies were more likely to receive HBV testing.The prevalence of hepatitis B surface antigen (HBsAg) positivity was 13.4%.HBV reactivation (appearance of HBV DNA or an increase in HBV DNA levels by 1 log 10) was observed in 33.1% (53/160) of the patients after chemotherapy.Among patients without prophylactic antiviral therapy,the reactivation rate was 43.9% (43/98) in the solid tumor group.Two reactivation cases occurred in patients who were HBsAg negative,but positive for hepatitis B core antibody.HBV reactivation was more likely to occur in patients with lymphoma,high levels of HBV DNA,or hepatitis B e antigen,and in men.CONCLUSION:Less than 20% of patients received HBV testing before chemotherapy.HBV reactivation would have occurred in about 50% of infected patients with solid tumors without antiviral prophylaxis.
基金Supported by National Natural Science Foundation of China,No.81273735Science and Technology Planning Project of Guangdong Province,China,No.2013B021800169Traditional Chinese Medicine Science and Technology Research Projects of Guangdong Provincial Hospital of Chinese Medicine,China,No.YN2014ZH05
文摘There are several malignancies of the digestive system(including gastric, pancreatic and colorectal cancers, and hepatocellular carcinoma), which are the most common types of cancer and a major cause of death worldwide. MicroRNA(miR)-7 is abundant in the pancreas, playing an important role in pancreatic development and endocrine function. Expression of miR-7 is downregulated in digestive system malignancies compared with normal tissue. Although there are contrasting results for miR-7 expression, almost all research reveals that miR-7 is a tumor suppressor, by targeting various genes in specific pathways. Moreover, miR-7 can target different genes simultaneously in different malignancies of the digestive system. By acting on many cytokines, miR-7 is also involved in many gastrointestinal inflammatory diseases as a significant carcinogenic factor. Consequently, miR-7 might be a biomarker or therapeutic target gene in digestive system malignancies.
